Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: A randomized trial

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 61, Issue 3, 2006, Pages 375-381

  Kaufmann, R ^a   Bieber, T ^b   Helgesen, A L ^c   Andersen, B Lasthein ^d   Luger, T ^e   Poulin, Y ^f   Al Hafidh, J ^g   Paul, C ^g  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Det Gule Pakhus   (Denmark)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f UNIVERSITÉ LAVAL   (Canada)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atopic dermatitis; Pimecrolimus; Pruritus relief

Indexed keywords

PIMECROLIMUS;

ACNE; AGED; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; FEMALE; FOLLICULITIS; HUMAN; INFECTION; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; SKIN BURNING SENSATION; SKIN DISEASE; SOFT TISSUE DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PROBABILITY; PRURITUS; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 33644912588     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2005.00977.x     Document Type: Article

References (31)

1. Pfeifer-Ott B Godfrey J Patients report many different signs and symptoms as indicators of impending flare in atopic eczema J Eur Acad Dermatol Venereol 2003 17 Suppl. 3 181
2. McCuaig C The itch that rashes: an update on atopic dermatitis Can J Diagnosis 2003 20 69 76
3. Stander S Steinhoff M Pathophysiology of pruritus in atopic dermatitis: an overview Exp Dermatol 2002 11 12 24
4. Giannetti A Fantini F Cimitan A Pincelli C Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis Acta Derm Venereol Suppl (Stockh) 1992 176 90 92
5. Stander S Steinhoff M Schmelz M Weisshaar E Metze D Luger T Neurophysiology of pruritus: cutaneous elicitation of itch Arch Dermatol 2003 139 1463 1470
6. Wahlgren CF Scheynius A Hagermark O Antipruritic effect of oral cyclosporin A in atopic dermatitis Acta Derm Venereol 1990 70 323 329
7. Herman SM Vender RB Antihistamines in the treatment of atopic dermatitis J Cutan Med Surg 2003 7 467 473
8. Kawashima M Tango T Noguchi T Inagi M Nakagawa H Harada S Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study Br J Dermatol 2003 148 1212 1221
9. Boguniewicz M Treatment options and new therapeutic approaches in atopic dermatitis Dermatol Nurs 2003 Suppl. 12 18
10. Savin JA Paterson WD Adam K Oswald I Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema Arch Dermatol 1979 115 313 315
11. Doxepin cream for eczema? Drug Ther Bull 2000 38 31 32
12. Grassberger M Baumruker T Enz A Hiestand P Hultsch T Kalthoff F et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology Br J Dermatol 1999 141 264 273
13. Kalthoff FS Chung J Stuetz A Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells Clin Exp Immunol 2002 130 85 92
14. Erratum in Clin Exp Immunol 2002 130 562 563
15. Winiski A Wang S Schwendinger B Stuetz A Inhibitory activity of pimecrolimus and tacrolimus on induced cytokine mRNA and protein expression in a human T-cell line (Jurkat) measured via RT-PCR and ELISA J Invest Dermatol 2002 119 347 (Abstract 835)
16. Hultsch T Muller KD Meingassner JG Grassberger M Schopf RE Knop J Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner Arch Dermatol Res 1998 290 501 507
17. Zuberbier T Chong SU Grunow K Guhl S Welker P Grassberger M et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils J Allergy Clin Immunol 2001 108 275 280
18. Eichenfield LF Lucky AW Boguniewicz M Langley RG Cherill R Marshall K et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents J Am Acad Dermatol 2002 46 495 504
19. Kapp A Papp K Bingham A Folster-Holst R Ortonne JP Potter PC et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug J Allergy Clin Immunol 2002 110 277 284
20. Meurer M Folster-Holst R Wozel G Weidinger G Junger M Brautigam M et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study Dermatology 2002 205 271 277
21. Queille-Roussel C Paul C Duteil L Lefebvre MC Rapatz G Zagula M et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study Br J Dermatol 2001 144 507 513
22. Wahn U Bos JD Goodfield M Caputo R Papp K Manjra A et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children Pediatrics 2002 110 e2
23. Bernard LA Eichenfield LF Topical immunomodulators for atopic dermatitis Curr Opin Pediatr 2002 14 414 418
24. Hochberg Y A sharper Bonferroni procedure for multiple tests of significance Biometrika 1988 75 800 802
25. Westfall PH Krishen A Optimally weighted, fixed sequence and gatekeeper multiple testing procedures J Statist Planning Inference 2001 99 25 40
26. Fivenson D Arnold RJ Kaniecki DJ Cohen JL Frech F Finlay AY The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization J Manag Care Pharm 2002 8 333 342
27. Ben-Gashir MA Relationship between quality of life and disease severity in atopic dermatitis/eczema syndrome during childhood Curr Opin Allergy Clin Immunol 2003 3 369 373
28. Kapp A Allen BR Reitamo S Atopic dermatitis management with tacrolimus ointment (Protopic) J Dermatolog Treat 2003 14 5 16
29. Wahlgren CF Hagermark O Bergstrom R Hedin B Evaluation of a new method of assessing pruritus and antipruritic drugs Skin Pharmacol 1988 1 3 13
30. Barbier N Paul C Luger T Allen R de Prost Y Papp K et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical progamme Br J Dermatol 2004 150 96 102
31. Kaufmann R Fölster-Holst R Höger P Thaçi D Löffler H Staab D et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants J Clin Allergy Immunol 2004 114 1183 1188